The NHL Alumni Association has signed a landmark agreement with Canopy Growth Corp., that will see the Canadian cannabis company finance one or more studies that could be an important step towards establishing the first comprehensive snapshot of the health of retired hockey players.
Canopy Growth has agreed to cover the costs of a double blind randomized study, which will involve about 100 former players in the Toronto area and take about a year to produce results, according to a person familiar with the matter.
New study led by NEEKA Health Canada will test if CBD-based therapies can reduce the severity of post-concussion brain disorders in former NHL players.
TORONTO & SMITHS FALLS, ON — NHL Alumni Association (NHLAA), NEEKA Health Canada and Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NYSE:CGC) are pleased to announce a transformative clinical research partnership that will investigate the efficacy of cannabinoids as an integral part of a novel treatment for post-concussion neurological diseases in former NHL players.
The first robotically assisted brain surgery in Vietnam took place on February 15 and was carried out by Doctor Chu Tan Si, Head of the hospital’s Neurology Department, and his colleagues with the support of Prof. Amin Kassam – Vice President of Aurora Health Care (USA). He is an expert in neurosurgery and also the person who came up with the idea of the robot system.
A leading hospital in Ho Chi Minh City has performed a successful robot-assisted surgery to remove a patient’s brain tumor using the Modus V digital microscope, marking the first time the device was used in an operation in Asia. The brain surgery was performed on Friday by doctors at the 115 General Hospital in District 10 with support from Prof. Amin Kassam, vice president of the U.S.-based Aurora Neuroscience Innovation Institute.